New global real-world data from AF studies confirm safety profile of XARELTO(R)
Janssen Pharmaceuticals and its development partner, Bayer HealthCare, announced results from PMSS and XANTUS (XARELTO® for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating safety of XARELTO® in people with NVAF. September 01, 2015